MX2017013696A - Sustancia biologicamente activa proveniente de una planta que tiene un efecto polifarmacologico. - Google Patents
Sustancia biologicamente activa proveniente de una planta que tiene un efecto polifarmacologico.Info
- Publication number
- MX2017013696A MX2017013696A MX2017013696A MX2017013696A MX2017013696A MX 2017013696 A MX2017013696 A MX 2017013696A MX 2017013696 A MX2017013696 A MX 2017013696A MX 2017013696 A MX2017013696 A MX 2017013696A MX 2017013696 A MX2017013696 A MX 2017013696A
- Authority
- MX
- Mexico
- Prior art keywords
- flavonoid
- effect
- virus
- rhamnazin
- tricin
- Prior art date
Links
- 229940088623 biologically active substance Drugs 0.000 title abstract 4
- 230000000694 effects Effects 0.000 title abstract 3
- -1 tricin flavonoid Chemical class 0.000 abstract 10
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 abstract 8
- 229930003935 flavonoid Natural products 0.000 abstract 7
- 235000017173 flavonoids Nutrition 0.000 abstract 7
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 abstract 6
- 229930182486 flavonoid glycoside Natural products 0.000 abstract 6
- MYMGKIQXYXSRIJ-UHFFFAOYSA-N rhamnacene Chemical compound C=1C(OC)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(OC)=C1 MYMGKIQXYXSRIJ-UHFFFAOYSA-N 0.000 abstract 6
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 abstract 5
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 abstract 5
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 abstract 5
- IDDMFNIRSJVBHE-UHFFFAOYSA-N Piscigenin Natural products COC1=C(O)C(OC)=CC(C=2C(C3=C(O)C=C(O)C=C3OC=2)=O)=C1 IDDMFNIRSJVBHE-UHFFFAOYSA-N 0.000 abstract 4
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 abstract 4
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 abstract 4
- 241000700605 Viruses Species 0.000 abstract 4
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 abstract 4
- 235000008714 apigenin Nutrition 0.000 abstract 4
- 229940117893 apigenin Drugs 0.000 abstract 4
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 abstract 4
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 abstract 4
- 235000009498 luteolin Nutrition 0.000 abstract 4
- 229960001285 quercetin Drugs 0.000 abstract 4
- 235000005875 quercetin Nutrition 0.000 abstract 4
- BMCJATLPEJCACU-UHFFFAOYSA-N tricin Natural products COc1cc(OC)c(O)c(c1)C2=CC(=O)c3c(O)cc(O)cc3O2 BMCJATLPEJCACU-UHFFFAOYSA-N 0.000 abstract 4
- 230000000840 anti-viral effect Effects 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- HRGUSFBJBOKSML-UHFFFAOYSA-N 3',5'-di-O-methyltricetin Chemical compound COC1=C(O)C(OC)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 HRGUSFBJBOKSML-UHFFFAOYSA-N 0.000 abstract 2
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 abstract 2
- 150000002215 flavonoids Chemical class 0.000 abstract 2
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 abstract 1
- 241000743799 Calamagrostis Species 0.000 abstract 1
- 241000744363 Deschampsia Species 0.000 abstract 1
- 241000196324 Embryophyta Species 0.000 abstract 1
- 241000711549 Hepacivirus C Species 0.000 abstract 1
- 208000005176 Hepatitis C Diseases 0.000 abstract 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 abstract 1
- 206010061598 Immunodeficiency Diseases 0.000 abstract 1
- 208000029462 Immunodeficiency disease Diseases 0.000 abstract 1
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- 241000209504 Poaceae Species 0.000 abstract 1
- 241000700584 Simplexvirus Species 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- 235000013339 cereals Nutrition 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000007955 flavonoid glycosides Chemical class 0.000 abstract 1
- 208000002672 hepatitis B Diseases 0.000 abstract 1
- 230000007813 immunodeficiency Effects 0.000 abstract 1
- 239000000411 inducer Substances 0.000 abstract 1
- 206010022000 influenza Diseases 0.000 abstract 1
- 229940079322 interferon Drugs 0.000 abstract 1
- 150000003254 radicals Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 241000712461 unidentified influenza virus Species 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
La invención se refiere a la farmacología y se puede usar para producir agentes medicinales para tratar y prevenir enfermedades virales causadas por los virus del herpes, influenza y la hepatitis ? y C, y también inmunodeficiencias inducidas por virus. Una sustancia biológicamente activa que tiene un efecto polifarmacológico está hecha de las partes verdes y las espiguillas de los cereales de la familia Gramineae, del género Calamagrostis Adans y/o del género Deschampsia Beauv, y contiene flavonoides, específicamente agliconas de los flavonoides tricina, apigenina, luteolina, quercetina y ramnazina, y/o glucósidos flavonoides de tricina, apigenina, luteolina, quercetina y ramnazina, y excipientes, y tiene la siguiente composición en porcentaje en masa: tricina flavonoide aglicona y/o tricina flavonoide glucósidos: 0.016-2062%; apigenina flavonoide aglicona y/o apigenina flavonoides glucósidos: 0.010-1.393%; luteolina flavonoide aglicona y/o luteolin flavonoides glucósidos: 0.01-4.979%; quercetina flavonoide aglicona y/o quercetina flavonoides glucósidos: 0.001-0.771%; ramnazina flavonoide aglicona y/o ramnazina flavonoide glucósidos: 0.104-0.203%; excipientes: 99.868-90.592%. De esta forma, la sustancia biológicamente activa se perfecciona determinando las composiciones específicas de los ingredientes activos de las mismas, y las características físicas, químicas y biológicas de las mismas, dando como resultado la invención de una composición óptima (Figura 1) para lograr un efecto antiviral con respecto a virus específicos, y dosis cuando se crean formas medicinales. Además, se ha determinado que la sustancia biológicamente activa es un inductor de un interferón endógeno tipo-?, que muestra un efecto modulador de la apoptosis, teniendo propiedades antioxidantes y mejorando la resistencia celular al estrés de radicales libres. Se ha establecido que el efecto antiviral con respecto a virus específicos es un efecto antiviral con respecto al virus del herpes simple tipo 2, el virus de la influenza y el virus de la diarrea viral bovina (virus de la hepatitis C).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAA201503915 | 2015-04-24 | ||
| PCT/UA2015/000101 WO2016171640A1 (ru) | 2015-04-24 | 2015-10-28 | Биологически активное вещество полифармакологического действия растительного происхождения |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017013696A true MX2017013696A (es) | 2019-07-29 |
Family
ID=67998792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017013696A MX2017013696A (es) | 2015-04-24 | 2015-10-28 | Sustancia biologicamente activa proveniente de una planta que tiene un efecto polifarmacologico. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20180133278A1 (es) |
| EP (1) | EP3195872A4 (es) |
| KR (1) | KR102461853B1 (es) |
| CN (1) | CN107530390A (es) |
| AU (1) | AU2015391981B2 (es) |
| BR (1) | BR112017021292A2 (es) |
| CA (1) | CA2983299C (es) |
| EA (1) | EA033232B1 (es) |
| MX (1) | MX2017013696A (es) |
| WO (1) | WO2016171640A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8933078B2 (en) | 2011-07-14 | 2015-01-13 | Research Cancer Institute Of America | Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances |
| US11890292B2 (en) | 2017-02-27 | 2024-02-06 | Research Cancer Institute Of America | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms |
| WO2018170457A1 (en) | 2017-03-17 | 2018-09-20 | Research Cancer Institute Of America | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms |
| WO2021262749A1 (en) * | 2020-06-26 | 2021-12-30 | Research Cancer Institute Of America | Compositions and methods for preventing and/or treating viral infection |
| CN113880898B (zh) * | 2020-10-30 | 2023-07-25 | 杭州拉林智能科技有限公司 | 黄酮苷-有机胺类抗微生物剂复盐化合物及其制备方法和应用 |
| CN114796016B (zh) * | 2022-05-31 | 2023-03-24 | 浙江伊瑟奇医药科技有限公司 | 一种私密修护精华液及其制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA54362C2 (en) * | 2002-12-26 | 2004-09-15 | Viktor Petrovych Atamaniuk | Method for isolating biologically active substance |
| DE102007054985A1 (de) * | 2007-11-17 | 2009-05-20 | Gerhard Dr. Sauermann | Topische Produkte zur Reduzierung der Häufigkeit von Rezidiven bei Lippenherpes |
| CA2721566C (en) * | 2008-04-21 | 2016-04-05 | Herbonis Ag | Preparation and use of a plant extract from solanum glaucophyllum with an enriched content of 1,25-dihydroxyvitamin d3 glycosides and quercetin glycosides |
-
2015
- 2015-10-28 KR KR1020177032242A patent/KR102461853B1/ko active IP Right Grant
- 2015-10-28 EP EP15890050.6A patent/EP3195872A4/en active Pending
- 2015-10-28 US US15/569,076 patent/US20180133278A1/en not_active Abandoned
- 2015-10-28 CN CN201580079170.6A patent/CN107530390A/zh active Pending
- 2015-10-28 WO PCT/UA2015/000101 patent/WO2016171640A1/ru active Application Filing
- 2015-10-28 EA EA201700340A patent/EA033232B1/ru unknown
- 2015-10-28 MX MX2017013696A patent/MX2017013696A/es unknown
- 2015-10-28 CA CA2983299A patent/CA2983299C/en active Active
- 2015-10-28 AU AU2015391981A patent/AU2015391981B2/en active Active
- 2015-10-28 BR BR112017021292-7A patent/BR112017021292A2/pt not_active IP Right Cessation
-
2020
- 2020-01-21 US US16/748,762 patent/US20220000962A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20180133278A1 (en) | 2018-05-17 |
| WO2016171640A8 (ru) | 2018-03-08 |
| KR20170139049A (ko) | 2017-12-18 |
| KR102461853B1 (ko) | 2022-10-31 |
| US20220000962A1 (en) | 2022-01-06 |
| WO2016171640A1 (ru) | 2016-10-27 |
| EP3195872A4 (en) | 2018-04-11 |
| CA2983299A1 (en) | 2016-10-27 |
| EP3195872A1 (en) | 2017-07-26 |
| EA033232B1 (ru) | 2019-09-30 |
| BR112017021292A2 (pt) | 2018-12-04 |
| CA2983299C (en) | 2022-12-06 |
| CN107530390A (zh) | 2018-01-02 |
| AU2015391981B2 (en) | 2021-08-19 |
| EA201700340A1 (ru) | 2017-10-31 |
| AU2015391981A1 (en) | 2017-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA033232B1 (ru) | Биологически активное вещество полифармакологического действия растительного происхождения | |
| Lawrence et al. | Rabies virus is recognized by the NLRP3 inflammasome and activates interleukin-1β release in murine dendritic cells | |
| Wan et al. | Baicalin inhibits TLR7/MYD88 signaling pathway activation to suppress lung inflammation in mice infected with influenza A virus | |
| WO2008036932A3 (en) | Compositions and methods comprising boswellia species | |
| PH12020550051A1 (en) | Glp-1 compositions and uses thereof | |
| WO2017019891A3 (en) | Compositions and methods for silencing hepatitis b virus gene expression | |
| NO20085243L (no) | Farmasoytisk sammensetning til behandling av virusinfeksjoner og/eller tumorsykdommer gjennom inhibering av proteinfolding og Proteinnedbryting | |
| WO2016183366A3 (en) | Compositions and methods for silencing expression of hepatitis d virus rna | |
| MX2009012299A (es) | Farmacos antivirales para el tratamiento o prevencion de la infeccion del dengue. | |
| EA200870304A1 (ru) | Псевдоинфекционный флавивирус и его применение | |
| BRPI0510016B8 (pt) | vetor lentiviral recombinante, composição imunogênica e uso dos mesmos como vacina | |
| MX2021010145A (es) | Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb. | |
| MX2020008125A (es) | Composiciones que comprenden berberina. | |
| EP4400098A3 (en) | Co-amorphous forms of beta-lactoglobulin and a drug substance | |
| DE602006014720D1 (de) | Immunstimulatorische kombination zur vorbeugung und behandlung von hepatitis c | |
| DE50112128D1 (de) | Retardpartikeldispersion | |
| WO2004085682A3 (de) | Caspase inhibitoren, insbesondere von caspase-3, zur behandlung von influenza | |
| MX2022002766A (es) | Vacunas contra el virus de la gripe y usos de las mismas. | |
| WO2011150320A3 (en) | Activators of innate immunity | |
| BR112021019845A2 (pt) | Composições de vírus inativado e formulações de vacina contra zika | |
| MX2023008004A (es) | Derivado de adenosina y composicion farmaceutica que lo comprende. | |
| WO2004089983A3 (en) | Severe acute respiratory syndrome (sars) causing coronavirus | |
| George et al. | Antiviral activity of a standardized root water extract of Eurycoma longifolia (Physta®) against dengue virus. | |
| MX2022005317A (es) | Prevencion de formacion de particulas visibles en soluciones acuosas de proteina. | |
| UA95299C2 (ru) | Профилактический или терапевтический агент против вирусного заболевания, вызванного вирусом гепатита с |